<DOC>
	<DOCNO>NCT00209898</DOCNO>
	<brief_summary>Hepatitis C infection prevalent chronic disease . It particularly prevalent among intravenous drug abuser . Bergen fengsel regional prison housing 250 inmate , many 70 record HCV RNA PCR positive annuallly . In study inmate male female randomize standard screen initiation procedure , rapid initiation procedure hospital 's infectious disease outpatient clinic . The study aim study rapid inclusion increase possibility conclude treatment prisoner still incarcerate , thus improve chance reach sustain virologic response , compare standard inclusion , prisoner , patient wait inclusion several month .</brief_summary>
	<brief_title>Hepatitis C Treatment Inmates</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Serologic evidence chronic hepatitis C infection antiHCV test Serum HCVRNA quantifiable &gt; 600 IU/mL 1000 copies/mL Roche AMPLICOR HCV MONITOR Test , v2.0 Patients normal elevated serum ALT eligible Compensated liver disease ( ChildPugh grade A clinical classification ) Patients cirrhosis transition cirrhosis must abdominal ultrasonography , CT scan MRI scan without evidence hepatocellular carcinoma serum AFP &lt; 100 ng/mL within 2 month randomization Negative urine blood pregnancy test ( woman childbearing potential ) document within 24 hour period prior first dose study drug All fertile male females receive RBV must use two form effective contraception treatment 6 month treatment end Women ongoing pregnancy breat feed Therapy systemic antiviral , antineoplastic immunomodulatory treatment ( include supraphysiologic sos steroid radiation ) &lt; 6 month prior first dose study drug Any investigational drug &lt; 6 week prior first dose study drug Positive test screen antiHAV IgM Ab , HBsAg , antiHBsAg , antiHBc Ab , antiHIV Ab . History evidence medical condition associate chronic liver disease HCV ( e.g . hemochromatosis , autoimmune hepatitis , metabolic liver disease , alcoholic liver disease , toxin exposure ) History evidence bleed esophageal varix condition consistent decompensated liver disease Neutrophil count &lt; 1500/mm platelet count &lt; 90,000 cells/mm screen Serum creatinine level &gt; 1,5 time ULN screen History severe psychiatric disease , especially depression . Severe psychiatric disease define treatment antidepressant medication neuroleptica therapeutic dos major depression psychosis , respectively least 3 month previous time , history follow ; suicidal attempt , hospitalization psychiatric disease period disability due psychiatric disease History severe seizure disorder current anticonvulsant disease History immunologically mediate disease ( e.g . IBD , ITP , LED , AIHA , scleroderma , severe psoriasis RA etc . ) History evidence chronic pulmonary disease associate functional limitation History major organ transplantation exist functional graft History severe cardiac disease ( e.g . NYHA Functional Class III IV , myocardial infarction within 6 month ventricular arrhythmia require ongoing treatment , unstable angina significant CVD ) History evidence severe illness , malignancy condition would make patient , opinion investigator , unsuitable study Evidence severe retinopathy ( e.g . CMV retinitis , macula degeneration ) Evidence ongoing drug abuse ( include excessive alcohol consumption ) Inability unwillingness provide inform consent abide requirement study Male partner woman pregnant Hemoglobin &lt; 12 g/dL woman &lt; 13g/dL men screen Any patient increase baseline risk anemia anemia would medically problematic Patients document presumed coronary artery disease cerebrovascular disease enrol , judgement investigator , acuter decrease hemoglobin 4 g/dL would welltolerated</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2003</verification_date>
	<keyword>Chronic hepatits C</keyword>
	<keyword>peginterferon</keyword>
	<keyword>ribavirin</keyword>
	<keyword>inmate</keyword>
	<keyword>fast initiation procedure</keyword>
</DOC>